Lexatumumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TRAIL-R2 |
| Identifiers | |
| CAS Number | 845816-02-6  |
| ATC code | none |
| UNII | 967Q0SJD77  |
| KEGG | D06611 |
| Chemical data | |
| Formula | C6346H9832N1720O2002S42 |
| Molecular mass | 143.6 kDa |
| (what is this?) (verify) |
|
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.[1]
HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2]
References
- ↑ Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association.
- ↑ http://www.hgsi.com/trail-receptor-antibodies-5.html
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Experimental cancer drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
